Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334884 | 1.00 | HTR2A (0.46) | HTR2ASSTR4CNR1CNR2CTSD | |
| SCHEMBL5019354 | 0.80 | HTR2A (0.50) | HTR2ASSTR4CNR1CNR2TRPV1 | |
| SCHEMBL31595597 | 0.80 | HTR2A (0.50) | HTR2ASSTR4CNR1CNR2TRPV1 | |
| SCHEMBL22997177 | 0.74 | PDPK1 (0.52) | HTR2A | |
| SCHEMBL29858433 | 0.74 | PDPK1 (0.52) | HTR2A | |
| SCHEMBL7500388 | 0.74 | PDPK1 (0.52) | HTR2A | |
| SCHEMBL130896 | 0.74 | PDPK1 (0.52) | HTR2A | |
| SCHEMBL11666222 | 0.74 | HTR2A (0.45) | HTR2ABACE1ENPP2 | |
| SCHEMBL7857614 | 0.74 | HTR2A (0.51) | HTR2ASSTR4CNR1CNR2TRPV1 | |
| SCHEMBL7502205 | 0.73 | HTR2A (0.51) | HTR2ACNR1CNR2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | HTR2A 2030/4885SSTR4 1238/4885CNR1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.